40 documents

Read All
15:04 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Summit discontinues DMD program after Phase II miss

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the Phase II PhaseOut DMD trial to treat Duchenne muscular dystrophy (DMD). PhaseOut DMD enrolled 40 DMD patients ages...
Read More
18:57 , Jun 27, 2018 |  BC Extra  |  Clinical News

Summit craters after ending DMD program

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the Phase II PhaseOut DMD trial to treat Duchenne muscular dystrophy. Summit sank 160p (81%) to 37.50p in London,...
Read More
20:57 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Summit's ezutromid reduces muscle damage in DMD

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) reported interim 24-week data from the Phase II PhaseOut DMD trial showing that twice-daily ezutromid (SMT C1100) reduced muscle damage in Duchenne muscular dystrophy patients. Compared to baseline, ezutromid significantly...
Read More
21:50 , Jan 25, 2018 |  BC Extra  |  Clinical News

Summit's ezutromid reduces muscle damage in DMD

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) gained $1.57 (13%) to $13.78 in New York on Thursday after reporting interim 24-week data from the Phase II PhaseOut DMD trial showing that twice-daily ezutromid (SMT C1100) reduced muscle...
Read More
19:11 , Oct 13, 2017 |  BioCentury  |  Regulation

Seeking surrogates

Thanks to flaws in PTC Therapeutics Inc. ’s trials, the recent FDA advisory committee meeting to discuss Translarna ataluren did nothing to clarify what level of dystrophin expression would be necessary to support an accelerated...
Read More
19:11 , May 19, 2017 |  BC Week In Review  |  Clinical News

Summit completes enrollment in Phase II DMD trial, receives $22M milestone from Sarepta

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) completed enrollment in the Phase II PhaseOut DMD trial of ezutromid (SMT C1100) to treat Duchenne muscular dystrophy (DMD), triggering a $22 million milestone payment from partner Sarepta Therapeutics Inc....
Read More
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Summit Therapeutics, Sarepta Therapeutics deal

Summit granted Sarepta exclusive commercialization rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit’s utrophin (UTRN) modulator pipeline to treat Duchenne muscular dystrophy (DMD). The deal includes Summit’s ezutromid, a small...
Read More
07:00 , Oct 4, 2016 |  BC Extra  |  Company News

Sarepta gets territorial rights to Summit's utrophin modulators

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) exclusive rights in Europe, Turkey and the Commonwealth of Independent States to Summit's utrophin ( UTRN ) modulator pipeline to treat Duchenne muscular dystrophy (DMD)....
Read More
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Ezutromid regulatory update

FDA granted rare pediatric disease designation to Summit’s ezutromid to treat Duchenne muscular dystrophy (DMD). The small molecule utrophin (UTRN) modulator is in Phase II testing (see BioCentury, June 27). Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT),...
Read More
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

Ezutromid: Phase II started

Summit began the 48-week, open-label, international Phase II PhaseOut DMD trial to evaluate oral ezutromid in up to 40 ambulatory male patients ages 5-10. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K.   Product: Ezutromid (formerly...
Read More